BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 24551261)

  • 21. Radiosensitizing effect of the novel Hsp90 inhibitor NVP-AUY922 in human tumour cell lines silenced for Hsp90α.
    Stingl L; Niewidok N; Müller N; Selle M; Djuzenova CS; Flentje M
    Strahlenther Onkol; 2012 Jun; 188(6):507-15. PubMed ID: 22441439
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anticancer agents suppressive for adult parasites of filariasis in Mongolian jirds.
    Kinnamon KE; Engle RR; Poon BT; Ellis WY; McCall JW; Dzimianski MT
    Proc Soc Exp Biol Med; 2000 May; 224(1):45-9. PubMed ID: 10782046
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Radiosensitization of HSF-1 Knockdown Lung Cancer Cells by Low Concentrations of Hsp90 Inhibitor NVP-AUY922.
    Kühnel A; Schilling D; Combs SE; Haller B; Schwab M; Multhoff G
    Cells; 2019 Sep; 8(10):. PubMed ID: 31569342
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The novel HSP90 inhibitor NVP-AUY922 shows synergistic anti-leukemic activity with cytarabine in vivo.
    Wendel T; Zhen Y; Suo Z; Bruheim S; Wiedlocha A
    Exp Cell Res; 2016 Jan; 340(2):220-6. PubMed ID: 26748184
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Visualising dual downregulation of insulin-like growth factor receptor-1 and vascular endothelial growth factor-A by heat shock protein 90 inhibition effect in triple negative breast cancer.
    Terwisscha van Scheltinga AG; Berghuis P; Nienhuis HH; Timmer-Bosscha H; Pot L; Gaykema SB; Lub-de Hooge MN; Kosterink JG; de Vries EG; Schröder CP
    Eur J Cancer; 2014 Sep; 50(14):2508-16. PubMed ID: 25027745
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Polyamines: agents with macrofilaricidal activity.
    Kinnamon KE; Engle RR; Poon BT; Ellis WY; McCall JW; Dzimianski MT
    Ann Trop Med Parasitol; 1999 Dec; 93(8):851-8. PubMed ID: 10715679
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting of multiple oncogenic signaling pathways by Hsp90 inhibitor alone or in combination with berberine for treatment of colorectal cancer.
    Su YH; Tang WC; Cheng YW; Sia P; Huang CC; Lee YC; Jiang HY; Wu MH; Lai IL; Lee JW; Lee KH
    Biochim Biophys Acta; 2015 Oct; 1853(10 Pt A):2261-72. PubMed ID: 25982393
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HSP90 inhibitor (NVP-AUY922) enhances the anti-cancer effect of BCL-2 inhibitor (ABT-737) in small cell lung cancer expressing BCL-2.
    Yang H; Lee MH; Park I; Jeon H; Choi J; Seo S; Kim SW; Koh GY; Park KS; Lee DH
    Cancer Lett; 2017 Dec; 411():19-26. PubMed ID: 28987383
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 89Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922.
    Nagengast WB; de Korte MA; Oude Munnink TH; Timmer-Bosscha H; den Dunnen WF; Hollema H; de Jong JR; Jensen MR; Quadt C; Garcia-Echeverria C; van Dongen GA; Lub-de Hooge MN; Schröder CP; de Vries EG
    J Nucl Med; 2010 May; 51(5):761-7. PubMed ID: 20395337
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel HSP90 inhibitors, NVP-AUY922 and NVP-BEP800, radiosensitise tumour cells through cell-cycle impairment, increased DNA damage and repair protraction.
    Stingl L; Stühmer T; Chatterjee M; Jensen MR; Flentje M; Djuzenova CS
    Br J Cancer; 2010 May; 102(11):1578-91. PubMed ID: 20502461
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antiproliferative effect of the HSP90 inhibitor NVP-AUY922 is determined by the expression of PTEN in esophageal cancer.
    Bao XH; Takaoka M; Hao HF; Fukazawa T; Yamatsuji T; Sakurama K; Takigawa N; Nakajima M; Fujiwara T; Naomoto Y
    Oncol Rep; 2013 Jan; 29(1):45-50. PubMed ID: 23064324
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antibiotics and Wolbachia in filarial nematodes: antifilarial activity of rifampicin, oxytetracycline and chloramphenicol against Onchocerca gutturosa, Onchocerca lienalis and Brugia pahangi.
    Townson S; Hutton D; Siemienska J; Hollick L; Scanlon T; Tagboto SK; Taylor MJ
    Ann Trop Med Parasitol; 2000 Dec; 94(8):801-16. PubMed ID: 11214099
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of Hsp90 augments docetaxel therapy in castrate resistant prostate cancer.
    Ku S; Lasorsa E; Adelaiye R; Ramakrishnan S; Ellis L; Pili R
    PLoS One; 2014; 9(7):e103680. PubMed ID: 25072314
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HSP90 inhibitor NVP-AUY922 enhances TRAIL-induced apoptosis by suppressing the JAK2-STAT3-Mcl-1 signal transduction pathway in colorectal cancer cells.
    Lee DH; Sung KS; Bartlett DL; Kwon YT; Lee YJ
    Cell Signal; 2015 Feb; 27(2):293-305. PubMed ID: 25446253
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Filarial infections of Mastomys natalensis and their relevance for experimental chemotherapy.
    Sänger I; Lämmler G; Kimmig P
    Acta Trop; 1981 Sep; 38(3):277-88. PubMed ID: 6118036
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification and localization of glutathione S-transferase as a potential target enzyme in Brugia species.
    Rao UR; Salinas G; Mehta K; Klei TR
    Parasitol Res; 2000 Nov; 86(11):908-15. PubMed ID: 11097299
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hsp90 inhibitor NVP-AUY922 enhances radiation sensitivity of tumor cell lines under hypoxia.
    Djuzenova CS; Blassl C; Roloff K; Kuger S; Katzer A; Niewidok N; Günther N; Polat B; Sukhorukov VL; Flentje M
    Cancer Biol Ther; 2012 Apr; 13(6):425-34. PubMed ID: 22286776
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Heat shock protein 90 inhibitor NVP-AUY922 exerts potent activity against adult T-cell leukemia-lymphoma cells.
    Taniguchi H; Hasegawa H; Sasaki D; Ando K; Sawayama Y; Imanishi D; Taguchi J; Imaizumi Y; Hata T; Tsukasaki K; Uno N; Morinaga Y; Yanagihara K; Miyazaki Y
    Cancer Sci; 2014 Dec; 105(12):1601-8. PubMed ID: 25263741
    [TBL] [Abstract][Full Text] [Related]  

  • 39. NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis.
    Eccles SA; Massey A; Raynaud FI; Sharp SY; Box G; Valenti M; Patterson L; de Haven Brandon A; Gowan S; Boxall F; Aherne W; Rowlands M; Hayes A; Martins V; Urban F; Boxall K; Prodromou C; Pearl L; James K; Matthews TP; Cheung KM; Kalusa A; Jones K; McDonald E; Barril X; Brough PA; Cansfield JE; Dymock B; Drysdale MJ; Finch H; Howes R; Hubbard RE; Surgenor A; Webb P; Wood M; Wright L; Workman P
    Cancer Res; 2008 Apr; 68(8):2850-60. PubMed ID: 18413753
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dual PI3K- and mTOR-inhibitor PI-103 can either enhance or reduce the radiosensitizing effect of the Hsp90 inhibitor NVP-AUY922 in tumor cells: The role of drug-irradiation schedule.
    Djuzenova CS; Fiedler V; Katzer A; Michel K; Deckert S; Zimmermann H; Sukhorukov VL; Flentje M
    Oncotarget; 2016 Jun; 7(25):38191-38209. PubMed ID: 27224913
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.